AlphaVax Secures $12.65 million in Series E funding

AlphaVax Inc., a Durham, N.C.-based developer of vaccine products for infectious diseases, biodefense and cancer, has raised approximately $12.65 million in Series E funding. No additional information was disclosed. www.alphavax.com